Pharsight

Drugs that contain Ixabepilone

1. Ixempra Kit patents expiration

IXEMPRA KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7022330 R-PHARM US LLC Parenteral formulation for epothilone analogs
Jan, 2022

(2 years ago)

US6670384 R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jan, 2022

(2 years ago)

USRE41393 R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Feb, 2022

(2 years ago)

US6670384

(Pediatric)

R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jul, 2022

(1 year, 7 months ago)

US7022330

(Pediatric)

R-PHARM US LLC Parenteral formulation for epothilone analogs
Jul, 2022

(1 year, 7 months ago)

USRE41393

(Pediatric)

R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Aug, 2022

(1 year, 6 months ago)

US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(5 months from now)

US7312237

(Pediatric)

R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Feb, 2025

(11 months from now)

Market Authorisation Date: 16 October, 2007

Treatment: Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to...

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

Family Patents